September 24, 2013
Teikoku Pharma USA, Inc. (TPU) announced that it has settled its claims for false and misleading advertising against JAR Laboratories LLC (JAR) as well as JAR’s counterclaims
Teikoku Pharma USA, Inc. (TPU) announced that it has settled its claims for false and misleading advertising against JAR Laboratories LLC (JAR) as well as JAR’s counterclaims. TPU filed suit in March 2012 in the United States District Court for the Eastern District of Illinois, based in Chicago, alleging claims for false advertising under the Lanham Act and various state laws. TPU alleged that JAR had engaged in false and misleading advertising in connection with the marketing and launch of its drug product “LidoPatch.”
In connection with the parties’ settlement, JAR stipulated to the district court’s entry of a Permanent Injunction, a copy of which can be accessed here.
The FDA approved Lidoderm® in 1999 for the relief of pain associated with post-herpetic neuralgia (a painful neurological condition that often follows an outbreak of the shingles virus). Lidoderm® is a prescription topical analgesic, self-adhesive patch containing lidocaine – a local anesthetic and topical analgesic- in the amount of 5% by weight.
Experts in the field have concluded that the therapeutic effectiveness of Lidoderm® stems from its proprietary hydrogel matrix formulation. That formulation delivers a controlled dose of lidocaine through the skin to provide an analgesic effect for its approved indication. Formulations that deliver more or less lidocaine through the skin have not been shown to be as effective (or more effective) than Lidoderm®.
About Teikoku Pharma USA
Teikoku Pharma USA, Inc., a wholly-owned subsidiary of Teikoku Seiyaku Co., Ltd., is a specialty pharmaceutical company that develops and manufactures enhanced pharmaceutical products with its transdermal drug delivery technology and the developer and maker of the leading topical analgesic transdermal patch – Lidoderm®, Teikoku focuses its efforts on two therapeutic areas: chronic and acute pain, and the central nervous system (CNS). Committed to applying its transdermal technology for the benefit of patients and partners, the company looks forward to exploring new fields of use for its proprietary systemic transdermal patch.
Teikoku Pharma USA, Inc.